Skip to Content

Alexion Pharmaceuticals, Inc.

Merger

  • Date:
  • 12/15/2020
  • Company Name:
  • Alexion Pharmaceuticals, Inc.
  • Stock Symbol:
  • ALXN
  • Company Name - Buyer:
  • AstraZeneca PLC
  • Stock Symbol - Buyer:
  • AZN
  • Status:
  • Investigating
  • Merger Announcement Date:
  • 12/12/2020

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by AstraZeneca PLC (NASDAQ: AZN).

On December 12, 2020, Alexion announced that it had signed an agreement to be acquired by AstraZeneca for approximately $39 billion.  Pursuant to the merger agreement, Alexion stockholders will receive $60 in cash and 2.1243 ADS (American depositary shares) for each share of Alexion common stock owned.  The deal is scheduled to close in the third quarter of 2021.

Bragar Eagel & Squire is concerned that Alexion’s board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement.  Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Alexion’s stockholders.

If you own shares of Alexion and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at investigations@bespc.com or telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Alexion Pharmaceuticals. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: